Funding Wizard

Attention San Joaquin Valley residents! The Valley Air District provides several great options to significantly reduce or even eliminate the pollution that comes from using your car.

The purpose of the Pesticide Environmental Stewardship Program Grant Initiative is to encourage smart, sensible and sustainable pest control in agriculture. The initiative, which is an extension of the Pesticide Environmental Stewardship Program (PESP), will enable grantees to implement sustainable pest management practices that align with the Agency’s strategic goal of providing a cleaner and healthier environment for all Americans and contribute to reductions in greenhouse gas emissions. Proposed projects should address implementation of environmentally sound pest management practices, approaches, training, and innovations that reduce the risks associated with pesticide use in agricultural settings and, where feasible, lead to corresponding reductions in greenhouse gas emissions that contribute to climate change. These projects will reduce unnecessary exposures to pests and pesticides through the adoption of integrated pest management practices and strengthen our shared goals of sustainable pest management and its intersection with climate change.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) – 2021 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 12, 2021. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates, the full text of the ROSES-2021 solicitation, and the "Summary of Solicitation" as a stand-alone document, may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2021. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2021table2 and http://solicitation.nasaprs.com/ROSES2021table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH21ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on “C.8 Lunar Data Analysis (.PDF)” to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read “C.1 Planetary Science Research Program Overview (.PDF)” from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2021 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2021 RSS feed for amendments, clarifications, and corrections to at http://science.nasa.gov/researchers/sara/grant-solicitations/ROSES-2021, and (3) The ROSES-2021 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The FY22 BMFRP IIRA will offer two funding levels with different intent:Funding Level 1 (FL1): To support studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in research, patient care, and/or quality of life in the FY22 BMFRP IIRA Focus Areas. IIRA applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, FL1 awards may not be used to support a clinical trial. Multidisciplinary collaborations are encouraged.Funding Level 2 (FL2): To support Investigational New Drug (IND)-enabling efforts. The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation. Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence. The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate(s). At least one, and no more than three, lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism. Library screening or drug optimization studies do not meet the intent of FL2. At the end of the period of performance, the cumulative data should be sufficient to submit an IND to the Food and Drug Administration (FDA). The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism. FL2 applications must address the FY22 BMFRP Focus Area “Find effective BMF treatments and cures”.The following are significant features of this award mechanism:• Impact: Proposed research projects should address a central critical issue or question in BMF disease research or clinical care. High-impact research, if successful, will significantly advance current methods and concepts for the prevention, detection, diagnosis, and/or treatment of BMF diseases.• Translational Potential: The translational potential of the project should be considered and described. Applications should address how the research will translate findings into prevention strategies and/or a cure for BMF diseases.• Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the BMFRP and support the proposed research project. Any unpublished preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team.• Multidisciplinary Collaborations: Applicants are encouraged, but not required, to form multidisciplinary teams of investigators who bring specific skills that contribute to the successful completion of the project. This can include both intellectual input and research resources (e.g., supplies, reagents, equipment, personnel, services, tissue samples, access to patients or populations).• Correlative Studies: Applications to FL1 are encouraged to propose correlative studies of open/ongoing or completed clinical trials to better characterize treatment response and provide deeper insights that can be used to develop future clinical trial endpoints or support personalized medicine approaches.Partnering PI Option: The IIRA encourages applications that include meaningful and productive collaborations between investigators and includes an option for more than one PI. Electing to submit to the partnering PI option does not influence the total direct cost limit as outlined in Section II.D.5, Funding Restrictions. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named to an individual award within the recipient organization. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

The Community Assistance Program - State Support Services element (CAP-SSSE) program provides funding to States to provide technical assistance to communities in the National Flood Insurance Program (NFIP) and to evaluate community performance in implementing NFIP floodplain management activities. Designation, duties, and responsibilities of State Coordinating Agencies are found in 44 CFR 60.25. These regulations identify the states commitment to the minimum floodplain management criteria and to demonstrate the capability and responsibility to implement the program. In this way, CAP-SSSE helps to; ensure that the flood loss reduction goals of the NFIP are met, build state and community floodplain management expertise and capability, and leverage state knowledge and expertise in working with their communities.

The LRP Idea Award supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. This award mechanism supports studies that have the potential to reveal entirely new avenues for investigation. The application must describe how the new idea will enhance the existing knowledge of lupus or develop a hypothesis(es) or an innovative and novel course of investigation. The Idea Award is not intended to support an incremental progression of an already established research project. Research completed through an Idea Award may generate sufficient preliminary data to enable the Principal Investigator (PI) to prepare an application for future research. Inclusion of preliminary data is not required.The following are important aspects of the Idea Award:• Innovation: Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. It is the responsibility of the PI to clearly and explicitly describe how the proposed research is innovative and will lead to novel avenues of investigation in lupus research.• Impact: The proposed research, if successful, should impact an area of paramount importance in lupus disease. Applications should clearly and explicitly describe the potential impact(s) of the proposed study for individuals living with lupus and to convey its level of significance. Research that represents an incremental advancement on previously published work is not considered impactful.• Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review.• Focus Areas: The proposed research must address at least one of the FY22 LRP Focus Areas.• Clinical trials are not allowed under this program announcement.The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY22 Idea Award will not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2023. For additional information refer to Section II.F.1, Federal Award Notices.The CDMRP expects to allot approximately $1.2M to fund approximately four Idea Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY22 funding opportunity will be funded with FY22funds, which will expire for use on September 30, 2023.

The intent of the FY22 CPMRP is to support studies that have the potential to make significant advances in the research, patient care and/or quality of life in the FY22 CPMRP IIRA Focus Areas. IIRA applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, this award may not be used to conduct clinical trials. Multidisciplinary collaborations and innovative approaches are encouraged. Studies seeking to advance new and novel opioid-based therapeutic interventions do not meet the intent of the award mechanism and will not be selected for funding. Studies seeking to understand and reduce opioid utilization in chronic pain management within the context of current prescribing practices are acceptable.

The DMDRP Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY22 DMDRP Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research. • The New Investigator – Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. • The New Investigator – Transitioning category is designed to allow established investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator – Early Stage category or New Investigator – Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI’s expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required.Key elements of this award are as follows: • Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. • Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress towards improving outcomes for individuals with DMD.

Academy of Kidney Cancer Investigators (AKCI) is a virtual career development and research mentoring platform that consists of Early-Career Scholar (ECS)/Designated Mentor pairs from different institutions, and an Academy Dean. The KCRP AKCIECSA is not a traditional career development award; the ECS is expected to conduct research, participate in monthly webinars, and annual workshops and to communicate and collaborate with other members of the Academy (other Early-Career Scholars, mentors, Dean) as well as with the kidney cancer advocacy community.The KCRP Academy of Kidney Cancer Investigators – Early-Career Scholar Award supports a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty emerging as potential leaders of kidney cancer research. The overarching goal of the AKCI is to advance kidney cancer research through development of highly productive kidney cancer researchers in a collaborative research and career development environment.The Academy Dean, selected in FY19, serves as a resource for the ECS and mentors, assessing the progress of the ECS, and facilitating communication and collaboration among all of the Early-Career Scholars and mentors, as well as with research and advocacy communities. In addition to fostering ECS scientific development, the AKCI, through its leadership by the Academy Dean, provides professional and leadership development of the ECS to include skills and competencies needed to fund and manage a productive laboratory or research team.This FY22 program announcement is soliciting Early-Career Scholars and Designated Mentors to join the existing Academy of Kidney Cancer Investigators. This award mechanism enables the ECS (the Scholar named as the Principal Investigator [PI] on the application) to pursue a kidney cancer project that may be basic, translational, and/or clinical research. The Designated Mentor is not required to be at the same institution as the ECS.The KCRP encourages applications from Early-Career Scholars whose ability to commit to conducting kidney cancer research is limited by minimal resources or a lack of resources, such as a qualified Designated Mentor at their institution, access to kidney cancer research tools, opportunities for establishing collaborations, or other obstacles, which should be identified in the application.Preliminary data to support the feasibility of the research applications and approaches are required; however, this data does not necessarily need to be derived from the kidney cancer research field.The ECS must be in the early-career stage. This award provides the ECS with funding, networking, and collaborative opportunities, and research experience necessary to develop and sustain a successful, independent career at the forefront of kidney cancer research. This award also provides support and protected time for the ECS for 4 years of intensive research under the guidance of a Designated Mentor experienced in kidney cancer research. Although the AKCI will serve as a conduit to share knowledge and research experience among all Academy members, the ECS and Designated Mentor will be responsible for developing the career development plans of the ECS and for designing and executing the proposed research. The ECS must clearly articulate their commitment to a career as a kidney cancer researcher and to participating in and contributing to the growth of the AKCI.The Designated Mentor must have a strong record of mentoring and training early-career investigators. With the goal to expand and enrich mentorship capacity within the Academy, a Designated Mentor must agree to also serve as a Secondary Mentor to another ECS in the Academy. The Designated Mentor will be limited to one Primary (applicant ECS/mentor pair) and one Secondary Mentorship. Applicants are not permitted to list the Dean of the Academy as a Designated Mentor. The ECS and Designated Mentor are required to attend a biennial multi-day Department of Defense (DOD) KCRP AKCI Workshop and, in alternate years, a 1-day DOD KCRP AKCI Workshop.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DOD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/0…) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY22 KCRP priorities.Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military families, and the American public. The anticipated direct costs budgeted for the entire period of performance for an FY22 KCRP AKCIECSA will not exceed $725,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2023. For additional information refer to Section II.F.1, Federal Award Notices.The CDMRP expects to allot approximately $3.48M to fund approximately three Academy of Kidney Cancer Investigators – Early-Career Scholar Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY22 funding opportunity will be funded with FY22 funds, which will expire for use on September 30, 2028.Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. Allow up to 3 months to complete the HRPO regulatory review and approval process following submission of all required and complete documents to the HRPO. Refer to the General Application Instructions, Appendix 1, and the Human Research Protections Office Resources and Overview document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.If the proposed research involves more than one institution a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.Clinical research is defined as: (1) Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies. (2) Epidemiologic and behavioral studies. (3) Outcomes research and health services research. Note: Studies that meet the requirements for Institutional Review Board (IRB) Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available. Clinical trials are not allowed. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Use of DOD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to active-duty military patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.Research Involving Animals: All research funded by the FY22 KCRP AKCIECSA involving new and ongoing research with animals must be reviewed and approved by the USAMRDC ORP Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions, Appendix 1, for additional information.Guidelines for Animal Research: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, SC, et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines 2.0 to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.

This funding opportunity announcement (FOA) invites applications to renew current ECHO Cohort Study Sites to extend and expand the capacity of the ECHO Cohort to further investigate the roles of a broad range of early exposures from society to biology, including the preconception period, on ECHOs five key child health outcome areaspre-, peri- and postnatal, upper and lower airways, obesity, neurodevelopment, and positive healthamong diverse populations. The objectives of this FOA are to solicit applications to 1) lead collaborative ECHO Cohort science 2) follow up existing ECHO Cohort participants, 3) recruit new pregnant participants from diverse populations, their resulting offspring, and, if available, the conceiving partner, 4) develop and implement the ECHO Cohort Preconception Pilot Study, and 5) implement the ECHO Cohort Data and Biospecimen Collection Protocol using the ECHO Cohort consortiums central data capture system, e.g., REDCap Central. This FOA does not support site-specific analyses and science. Only current ECHO Cohort awardees are eligible to apply. This new funding period will be 7 years in duration provided successful performance in the UG3 phase and the UH3 phase. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites only for a limited competition of follow-up of existing ECHO Cohort participants (RFA XXXX), for ECHO Cohort Study Sites only for an open competition of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA YYYY), for an ECHO Coordinating Center (RFA NNNN), for an ECHO Data Analysis Center (RFA NNNN), for an ECHO Measurement Core (RFA NNNN), and for an ECHO Laboratory Core (RFA NNNN).